LGVN Stock Analysis: Buy, Sell, or Hold?
LGVN - Longeveron Inc. Common Stock
$0.70
-0.05 (-6.94%)
▼
5d:
-17.52%
30d:
-37.27%
90d:
+31.52%
WAIT
LOW Confidence
Analysis Updated: May 14, 2026 12:00 AM ET
Earnings: May 13, 2026
0d
Get Alerted When LGVN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called LGVN this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: LGVN is down 17.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: LGVN is down 17.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: LGVN is currently trading at $0.70, which is considered oversold relative to its 30-day fair value range of $0.83 to $1.10.
Technical Outlook: Technically, LGVN is in a strong uptrend. The price is currently testing key support at $0.71. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 6.9% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $6.82 (+870.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, LGVN is in a strong uptrend. The price is currently testing key support at $0.71. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 6.9% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $6.82 (+870.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.83 -
$1.10
Company Quality Score
45/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-6.9%)
- BULLISH: Trading 870.2% below Wall St target ($6.82)
- WARNING: Recommendation downgraded due to -17.5% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$0.83 -
$1.10
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.71
Resistance Level
$0.90
Current Trend
Strong Uptrend
Technical data as of
May 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.38
Wall Street Target
$6.82
(+870.2%)
Revenue Growth (YoY)
-39.5%
Share & Embed Analysis
Last updated: May 15, 2026 7:34 AM ET
Data refreshes hourly during market hours. Next update: 8:34 AM
Data refreshes hourly during market hours. Next update: 8:34 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LGVN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$449 | 54 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$23 | 56 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$73 | 58 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 58 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$208 | 49 HOLD |
